These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22629725)

  • 21. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
    Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
    Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK.
    Wu P; Zhao J; Guo Y; Yu Y; Wu X; Xiao H
    Biochem Biophys Res Commun; 2020 Aug; 529(3):834-838. PubMed ID: 32595039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia.
    Fan JG; Zhong L; Tia LY; Xu ZJ; Li MS; Wang GL
    World J Gastroenterol; 2005 Apr; 11(15):2346-50. PubMed ID: 15818751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-alcoholic steato-hepatitis.
    Chawla Y; Amrapurkar D
    Trop Gastroenterol; 2002; 23(4):186-8. PubMed ID: 12833707
    [No Abstract]   [Full Text] [Related]  

  • 25. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
    Ratziu V; de Ledinghen V; Oberti F; Mathurin P; Wartelle-Bladou C; Renou C; Sogni P; Maynard M; Larrey D; Serfaty L; Bonnefont-Rousselot D; Bastard JP; Rivière M; Spénard J;
    J Hepatol; 2011 May; 54(5):1011-9. PubMed ID: 21145828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid.
    Perez MJ; Macias RI; Duran C; Monte MJ; Gonzalez-Buitrago JM; Marin JJ
    J Hepatol; 2005 Aug; 43(2):324-32. PubMed ID: 15970352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment.
    Ersöz G; Günşar F; Karasu Z; Akay S; Batur Y; Akarca US
    Turk J Gastroenterol; 2005 Sep; 16(3):124-8. PubMed ID: 16245220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of non-alcoholic steatohepatitis (NASH). A comparative study of ursodeoxycholic acid and alpha-tocopherol. A preliminary report].
    Bernal-Reyes R; Escudero RB
    Rev Gastroenterol Mex; 2002; 67(2):70-5. PubMed ID: 12214337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
    Georgescu EF; Georgescu M
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):39-46. PubMed ID: 17410287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
    Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
    Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.
    Arenas F; Hervias I; Uriz M; Joplin R; Prieto J; Medina JF
    J Clin Invest; 2008 Feb; 118(2):695-709. PubMed ID: 18188457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling.
    Marchianò S; Biagioli M; Roselli R; Zampella A; Di Giorgio C; Bordoni M; Bellini R; Urbani G; Morretta E; Monti MC; Distrutti E; Fiorucci S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Nov; 1867(11):159218. PubMed ID: 35985473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients.
    Fouda A; Abdelaziz AE; Hussien M; Ali AA; Abdelkawy KS; Elbarbry F
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7449-7459. PubMed ID: 34919247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Negative trials in nonalcoholic steatohepatitis: why they happen and what they teach us.
    Clark JM; Brancati FL
    Hepatology; 2004 Mar; 39(3):602-3. PubMed ID: 14999677
    [No Abstract]   [Full Text] [Related]  

  • 35. The treatment with ursodeoxycholic acid in elderly patients affected by NAFLD and metabolic syndrome: a case-control study.
    Troisi G; Crisciotti F; Gianturco V; D'Ottavio E; Lo Iacono C; Formosa V; Bernardini S; Bellomo A; Marigliano B; Marigliano V
    Clin Ter; 2013; 164(3):203-7. PubMed ID: 23868620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis.
    Lepage G; Paradis K; Lacaille F; Sénéchal L; Ronco N; Champagne J; Lenaerts C; Roy CC; Rasquin-Weber A
    J Pediatr; 1997 Jan; 130(1):52-8. PubMed ID: 9003851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical effect of the extract of TCM Fructus akebiae combined with ursodeoxycholic acid on nonalcoholic fatty liver disease.
    Hongguang J; Xingjie H; Mingliang J; Yun L; Tongjian L; Jingmo Y; Liang L; Lifang Z
    Pak J Pharm Sci; 2019 Jan; 32(1(Special)):433-437. PubMed ID: 30852481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psoriasis treated with ursodeoxycholic acid: three case reports.
    Itoh S; Kono M; Akimoto T
    Clin Exp Dermatol; 2007 Jul; 32(4):398-400. PubMed ID: 17376209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
    Shi J; Wu C; Lin Y; Chen YX; Zhu L; Xie WF
    Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NASH remains without a treatment ... URSO they say.
    Braegger C
    J Pediatr Gastroenterol Nutr; 2004 Sep; 39(3):305-6. PubMed ID: 15319640
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.